Patrick J. Heron, Director at Arcutis Biotherapeutics, Inc. (ARQT), bought 2,646 shares at $13.08 ($35K) on 2025-06-13, disclosed to the SEC on 2025-06-17.
Seasonal purchase ($35k) by Director — this insider has traded ARQT in June in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| Filing → |
| ARQT | BUY | 2025-05-23 | $69K | — | Filing → |
| ARQT | BUY | 2025-05-19 | $34K | — | Filing → |
| ARQT | BUY | 2025-05-15 | $119K | — | Filing → |